ÃÑ 67ÆäÀÌÁö

65ÆäÀÌÁö º»¹®½ÃÀÛ

°æ±âµµ ¿ä¾ç½Ã¼³ »çȸ¾à·á¼­ºñ½º µµÀÔ ¹× ½ÇÇà¹æ¾È
? Âü°í¹®Çå
1) º¸°Çº¹ÁöºÎ ÀǾàÇ° Á¤Ã¥ÆÀ, ÀǾàÇ° »ç¿ë°ú¿À(Medication Error)¿¹¹æÀ» À§ÇÑ °¡À̵å¶óÀÎ, 2008
2) Woo CM. Guidelines on medication error prevention. Seoul:Ministry of Health and Welfare 2008.
3) C A Bond, C L Raehl, T Franke, Medication Errors in United States Hospitals, 2001
4) Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients a
meta-analysis of prospective studies. JAMA. 1998; 279(15): 1200-5.
5) Keers RN, Williams SD, Cooke J, et al. Prevalence and Nature of Medication Administration Errors
in Health Care Settings: A Systematic Review of Direct Observational Evidence. Ann Pharmacotherapy.
2013; 47:237-56.
6) Lewis PJ, Dornan T, Taylor D, et al. Prevalence, Incidence and Nature of Prescribing Errors in
Hospital Inpatients: a Systematic Review. Drug Saf. 2009; 32(5):379-89.
7) Latif A, Rawat N, Pustavoitau A, et al. National Study on the Distribution, Causes, and
Consequences of Voluntarily Reported Medication Errors Between the ICU and Non-ICU Settings. Crit
Care Med. 2013; 41(2):389-98.
8) Bates DW, Spell N, Cullen DJ, et al. The Costs of Adverse Drug Events in Hospitalized Patients.
JAMA. 1997; 277(4):307-11.
9) Institute of Medicine. Preventing medication errors report. 2007.
10) Simeon Bennett, WHO launches global effort to halve medication-related errors in 5 years,
2017.03.29.
11) Kim, H, Kim, S., and Suh, H. S. : Current state of medication error in Korea: Analysis of
medication injury relief in Korea Consumer Agency, J. Health Tech. Assess. 7, 6, 2019
12) Á¤Ã¥¿¬±¸º»ºÎ °Å·¡Á¶»ç¿¬±¸ÆÀ, ÀǾàÇ° ºÎÀÛ¿ë ½ÇÅÂÁ¶»ç, 2008
13) 2020 ±¹¹Î°ú ÇÔ²²ÇÏ´Â ¾à»çÁ¤Ã¥ °ÇÀǼ­
14) ½ÄÇ°ÀǾàÇ°¾ÈÀüó, 2019³â ÀǾàÇ° ºÎÀÛ¿ë º¸°í µ¿Ç⠺м®, 2020
15) °Ç°­º¸Çè½É»çÆò°¡¿ø, 2018³â ±âÁØ ÀǾàÇ° ¼Òºñ·® ¹× ÆÇ¸Å¾× Åë°è »ý»ê, 2019
16) ÀüÇϸ², ¹ÚÁÖÈñ, ±èµ¿¼÷, ÃÖº´Ã¶, ÀǾàÇ° »ç¿ëÆò°¡(DUR) »ç¾÷ÀÇ ¹Ì±¹ 47°³¼ö Medicaid ÀÚ·á ºñ±³ ¹×
Á¤Ã¥Àû ÇÔÀÇ °íÂû, Çѱ¹º¸°Ç»çȸ¿¬±¸¿ø, 2014, 192-221
17) Åë°èû, 2019 °í·ÉÀÚÅë°è, 2019
18) º¸°Çº¹ÁöºÎ, 2017³âµµ ³ëÀÎ ½ÇÅ Á¶»ç °á°úº¸°í¼­, 2019
19) ¼Õµ¿·Ä, ³ëÀÎȯÀÚÀÇ ¾àµ¿¡¤¿ªÇÐÀû Ư¡°ú ¾à¹° »ç¿ëÀÇ ÁÖÀÇ»çÇ×, ´ëÇÑÀÓ»ó³ëÀÎÀÇÇÐÈ÷ Ãß°èÇмú´ëȸ,
2005
20) Oh JM. Drug use pattern and evaluation for appropriateness in geriatric patients. Research report
of Korea Food & Drug Administration 2004; 04142: 858-2.
21) ³ëÀÎÀå±â¿ä¾çº¸Çè¹ýÀÇ Àû¿ëÀ» ¹Þ´Â ³ëÀÎÀǷẹÁö½Ã¼³ Áß ³ëÀοä¾ç½Ã¼³Àº Ä¡¸Å¡¤Áßdz µî ³ëÀμºÁúȯ
µîÀ¸·Î ½É½Å¿¡ »ó´çÇÑ Àå¾Ö°¡ ¹ß»ýÇÏ¿© µµ¿òÀ» ÇÊ¿ä·Î ÇÏ´Â ³ëÀÎÀ» ÀÔ¼Ò½ÃÄÑ ±Þ½Ä¡¤¿ä¾ç°ú ±× ¹Û¿¡ ÀÏ
»ó»ýÈ°¿¡ ÇÊ¿äÇÑ ÆíÀǸ¦ Á¦°øÇÔÀ» ¸ñÀûÀ¸·Î ÇÔ.
22) ÃÖ¼÷ÀÚ ¿Ü. ¿ä¾çº´¿ø, ³ëÀοä¾ç½Ã¼³ÀÇ È¯ÀÚ ¾ÈÀü°ü¸®¿Í ÀǾàÇ° »ç¿ë. 2020
23) °­¼÷ ¿Ü. ³ëÀοä¾ç½Ã¼³ ³ëÀÎÀÇ ´Ù¾àÁ¦ º¹¿ë(Polypharmacy)°ú ºÎÀûÀýÇÑ ¾à¹°»ç¿ë ½ÇÅÂ. 2013
24) ¼Õâ¿ì, ¼­¿ï½Ã ÀÇ·á±Þ¿© ¼ö±Þ±ÇÀÚÀÇ °Ç°­°ü¸®¿Í ÀÇ·áÀÌ¿ë ½ÇÅÂ, ¼­¿ï¿¬±¸¿ø Á¤Ã¥¸®Æ÷Æ®, 2018
25) ¹ÚÀºÀÚ, ÀÌ¿¹½½, ÀÌÁ¤¾Æ, ±ÇÁø¿ø, »ýÈ°½À°üº´ Ä¡·á ¼øÀÀ ÇöȲ ¹× °³¼±¹æ¾È, Çѱ¹º¸°Ç»çȸ¿¬±¸¿ø, 2014
26) Åë°èû, 2019 °í·ÉÀÚÅë°è, 2019
27) º¸°Çº¹ÁöºÎ, 2017³âµµ ³ëÀÎ ½ÇÅ Á¶»ç °á°úº¸°í¼­, 2019
28) À±Á¾·ü ¿Ü. ÀÏ°³ ³ëÀκ¹Áö°ü ¹æ¹® ³ëÀÎȯÀÚµéÀÇ ´Ù¾àÁ¦º¹¿ë°ú ºÎÀûÀýÇÑ ¾à¹°Ã³¹æ ½ÇÅÂ. 2008
29) Gurwitz JH, el. Incidence and preventability of adverse drug events among older persons in the
- 61 -

65ÆäÀÌÁö º»¹®³¡



ÇöÀç Æ÷Ä¿½ºÀÇ ¾Æ·¡³»¿ëµéÀº µ¿ÀÏÇÑ ÄÁÅÙÃ÷¸¦ °¡Áö°í ÆäÀÌÁö³Ñ±è È¿°ú¹× ½Ã°¢Àû È¿°ú¸¦ Á¦°øÇÏ´Â ÆäÀÌÁöÀ̹ǷΠ½ºÅ©¸°¸®´õ »ç¿ëÀÚ´Â ¿©±â±îÁö¸¸ ³¶µ¶ÇϽðí À§ÀÇ ÆäÀÌÁöÀ̵¿ ¸µÅ©¸¦ »ç¿ëÇÏ¿© ´ÙÀ½ÆäÀÌÁö·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
»ó´Ü¸Þ´º ¹Ù·Î°¡±â ´ÜÃàÅ°¾È³» : ÀÌÀüÆäÀÌÁö´Â ÁÂÃø¹æÇâÅ°, ´ÙÀ½ÆäÀÌÁö´Â ¿ìÃø¹æÇâÅ°, ùÆäÀÌÁö´Â »ó´Ü¹æÇâÅ°, ¸¶Áö¸·ÆäÀÌÁö´Â ÇϴܹæÇâÅ°, ÁÂÃøÈ®´ëÃà¼Ò´Â insertÅ°, ¿ìÃøÈ®´ëÃà¼Ò´Â deleteÅ°